Canada markets close in 3 hours 57 minutes

CRISPR Therapeutics AG (1CG.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
40.800.00 (0.00%)
As of 08:10AM CEST. Market open.
Full screen
Previous Close40.80
Open38.20
Bid0.00 x 0
Ask0.00 x 0
Day's Range37.80 - 38.40
52 Week Range37.80 - 40.80
Volume40
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

    ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. The abstract describ

  • GlobeNewswire

    CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

    ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the

  • GlobeNewswire

    CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

    ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. Title: Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucom